$4.34
-0.26[-5.65%]
At close: Apr 23
$4.34
0[0.00%]
After Hours: 9:28AM EDT
Moleculin Biotech
(NASDAQ:MBRX)Moleculin Biotech Stock (NASDAQ:MBRX), Analyst Ratings, Price Targets, Predictions
Moleculin Biotech Inc has a consensus price target of $17, established from looking at the 6 latest analyst ratings. The last 3 analyst ratings were released from Roth MKM, Maxim Group, and HC Wainwright & Co. on April 12, 2024, March 26, 2024, and December 14, 2023. With an average price target of $21 between Roth MKM, Maxim Group, and HC Wainwright & Co., there's an implied 383.87% upside for Moleculin Biotech Inc from these 3 analyst ratings.
Analyst Firms Making Recommendations1
Roth MKM
Maxim Group
HC Wainwright & Co.
Oppenheimer
1calculated from analyst ratings published within the last 3 years
Analyst Ratings for Moleculin Biotech
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 04/12/2024 | MBRX | Buy Now | Moleculin Biotech | $4.34 | 821.66% | Roth MKM | Jonathan Aschoff | → $40 | Maintains | Buy | Get Alert |
| 03/26/2024 | MBRX | Buy Now | Moleculin Biotech | $4.34 | 360.83% | Maxim Group | Jason McCarthy | $45 → $20 | Maintains | Buy | Get Alert |
| 12/14/2023 | MBRX | Buy Now | Moleculin Biotech | $4.34 | -30.88% | HC Wainwright & Co. | Vernon Bernardino | → $45 | Initiates | → Buy | Get Alert |
| 04/18/2023 | MBRX | Buy Now | Moleculin Biotech | $4.34 | 268.66% | Roth MKM | Jonathan Aschoff | → $240 | Maintains | Buy | Get Alert |
| 03/24/2023 | MBRX | Buy Now | Moleculin Biotech | $4.34 | 15.21% | Oppenheimer | Jeff Jones | → $75 | Reiterates | → Outperform | Get Alert |
| 07/18/2022 | MBRX | Buy Now | Moleculin Biotech | $4.34 | 222.58% | Oppenheimer | Jeff Jones | $30 → $210 | Assumes | → Outperform | Get Alert |
FAQ
What is the target price for Moleculin Biotech (MBRX)?
The latest price target for Moleculin Biotech (NASDAQ: MBRX) was reported by Roth MKM on April 12, 2024. The analyst firm set a price target for $40.00 expecting MBRX to rise to within 12 months (a possible 821.66% upside). 3 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Moleculin Biotech (MBRX)?
The latest analyst rating for Moleculin Biotech (NASDAQ: MBRX) was provided by Roth MKM, and Moleculin Biotech maintained their buy rating.
When was the last upgrade for Moleculin Biotech (MBRX)?
There is no last upgrade for Moleculin Biotech.
When was the last downgrade for Moleculin Biotech (MBRX)?
There is no last downgrade for Moleculin Biotech.
When is the next analyst rating going to be posted or updated for Moleculin Biotech (MBRX)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Moleculin Biotech, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Moleculin Biotech was filed on April 12, 2024 so you should expect the next rating to be made available sometime around April 12, 2025.
Is the Analyst Rating Moleculin Biotech (MBRX) correct?
While ratings are subjective and will change, the latest Moleculin Biotech (MBRX) rating was a maintained with a price target of $0.00 to $40.00. The current price Moleculin Biotech (MBRX) is trading at is $4.34, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.